It’s Time to Buy the Dip in BIOLASE Inc. [BIOL] Stock

In a recent bid BIOLASE Inc. [BIOL] faced a contemporary bid of $0.32 yielding a 12.04% incline where 14.04 million shares have exchanged hands over the last week. BIOL amount got a fall by -13.66% or -$0.05 versus $0.37 at the end of the prior session. This change led market cap to move at 28.98M, putting the price 51.28% below the 52-week high and -66.75% above the 52-week low. The company’s stock has a normal trading capacity of 14.04 million shares while the relative volume is 5.07.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 17, November 2020, BIOLASE Announces the Launch of Waterlase Endo Academy. According to news published on Yahoo Finance, Waterlase endodontists invited to join community for advanced learning in endodontics.

Analyst Birdseye View:

The most recent analyst activity for BIOLASE Inc. [NASDAQ:BIOL] stock was on April 25, 2017, when it was Initiated with a Buy rating from Singular Research, which also raised its 12-month price target on the stock to $2.50. Before that, on June 19, 2019, The Benchmark Company Recapitulated a Speculative buy rating and elevated its amount target to $2. On May 13, 2014, WallachBeth Downgrade a Hold rating and plunged its price target on this stock from $4 to $2.50. On November 12, 2013, WallachBeth Reiterated a Buy rating and decreased its price target from $3.50 to $2.75. On August 08, 2013, WallachBeth Reiterated a Buy rating and decreased its price target to $4.50. On June 17, 2013, WallachBeth Initiated a Buy rating and boosted its amount on this stock to $6.50. On March 18, 2013, Northland Capital Reiterated an Outperform rating and boosted its target amount on this stock from $6 to $7. On March 07, 2013, Northland Capital Reiterated an Outperform rating and improved its amount target to $7.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.21 and a peak of $0.96. Right now, according to Wall Street analyst the average 12-month amount target is $1.41. At the most recent market close, shares of BIOLASE Inc. [NASDAQ:BIOL] were valued at $0.32.


BIOLASE Inc. [NASDAQ:BIOL] most recently reported quarterly sales of 6.54 billion, which represented growth of -24.40%. This publicly-traded organization’s revenue is $240,758 per employee, while its income is -$113,726 per employee. This company’s Gross Margin is currently 36.80%, its Operating Margin is -75.20%, its Pretax Margin is -47.35, and its Net Margin is -47.24. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -49.57, -231.42, -77.99 and -135.93 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 76.06 and the whole liability to whole assets at 42.09. It shows enduring liability to the whole principal at 0.02 and enduring liability to assets at 0.00 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 0.3081 points at 1st support level, the second support level is making up to 0.2971. But as of 1st resistance point, this stock is sitting at 0.3351 and at 0.3511 for 2nd resistance point.

BIOLASE Inc. [BIOL] reported its earnings at -$0.21 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.05/share signifying the difference of -0.16 and -320.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.12 calling estimates for -$0.17/share with the difference of 0.05 depicting the surprise of 29.40%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for BIOLASE Inc. [NASDAQ:BIOL] is 1.70. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.24. Now if looking for a valuation of this stock’s amount to sales ratio it’s 0.34 and it’s amount to book ratio is 46.10.

Insider Stories

The most recent insider trade was by FEINBERG LARRY N, 10% Owner, and it was the sale of 1.77 million shares on Jun 09. FEINBERG LARRY N, the 10% Owner, completed a sale of 3.4 million shares on Jun 08. On Feb 11, SCHULER JACK W, 10% Owner, completed a sale of 1.31 million shares.